CLAIMS

1. A spontaneously dispersible pharmaceutical composition comprising a 5-aryl-4(R)-arylcarbonylamino-pent-2-enoic acid amide substance P antagonist.

2. A spontaneously dispersible pharmaceutical composition comprising a 5-aryl-4(R)-arylcarbonylamino-pent-2-enoic acid amide substance P antagonist and a carrier medium comprising a lipophilic component, a surfactant, and optionally a hydrophilic component.

3. A pharmaceutical composition as claimed in claim 1 or 2 where the 5-aryl-4(R)-arylcarbonylamino-pent-2-enoic acid amide substance P antagonist is (4R)-4-[N'-methyl-N'-(3,5-bistrifluoro-methyl-benzoyl)amino]-4-(3,4-dichlorobenzyl)-but-2-enoic acid N-[(R)-epsilon-caprolactam-3-yl]-amide.

4. A pharmaceutical composition comprising (4R)-4-[N'-methyl-N'-(3,5-bistrifluoro-methyl-benzoyl)amino]-4-(3,4-dichlorobenzyl)-but-2-enoic acid N-[(R)-epsilon-caprolactam-3-yl]-amide as active agent and a carrier medium comprising a lipophilic component, a surfactant and optionally a hydrophilic component, said composition being in an form that is suitable for oral administration.

5. A composition as claimed in claim 2 or 4 wherein the lipophilic component comprises C_8-C_{10} fatty acid monoglycerides and diglycerides or a refined glycerol-transesterified corn oil.

6. A composition as claimed in any one of claims 2, 4 and 5 wherein the hydrophilic component comprises propylene glycol.

7. A composition as claimed in any one of claims 2, 4, 5 and 6 wherein the surfactant comprises a polyethyleneglycol-hydrogenated castor oil.

8. A spontaneously dispersible pharmaceutical composition comprising about 0.05 to about 20% by weight of (4R)-4-[N'-methyl-N'-(3,5-bistrifluoro-methyl-benzoyl)amino]-4-(3,4-dichlorobenzyl)-but-2-enoic acid N-[(R)-epsilon-caprolactam-3-yl]-amide, about 5 to about 85 % by weight of a lipophilic component, about 5 to about 90 % by weight of a

surfactant, and optionally about 5 to about 60 % by weight of a hydrophilic component, all weights based on the total composition.

9. A composition as claimed in any one of claims 1 to 8 in the form of a microemulsion preconcentrate.

10. A composition as claimed in any one of claims 1 to 8 in the form of a microemulsion.

11. A composition according to any preceding claim in unit dosage form.

12. A composition according to claim 11 in soft or hard gelatin encapsulated form.

13. A method of treatment of a subject suffering from a disorder treatable with a 5-aryl-4(R)-arylcarbonylamino-pent-2-enoic acid amide substance P antagonist comprising administering a therapeutically effective amount of a pharmaceutical composition as claimed in any preceding claim to a subject in need of such treatment.

14. A process for preparing a spontaneously dispersible pharmaceutical composition containing a 5-aryl-4(R)-arylcarbonylamino-pent-2-enoic acid amide substance P antagonist as an active agent, which process comprises bringing the active agent and a carrier medium comprising (1) a lipophilic component, (2) a surfactant, and optionally (3) a hydrophilic component into intimate admixture.

15. A process for the preparing a microemulsion containing a 5-aryl-4(R)-arylcarbonyl-amino-pent-2-enoic acid amide substance P antagonist as an active agent, which process comprises:

(i) bringing the active agent and a carrier comprising (1) a lipophilic component, (2) a surfactant, and optionally (3) a hydrophilic component into intimate admixture to form a spontaneously dispersible pharmaceutical composition; and

(ii) diluting the spontaneously dispersible pharmaceutical composition in an aqueous medium to form the microemulsion.

16. A spontaneously dispersible pharmaceutical composition comprising a 5-aryl-4(R)-arylcarbonylamino-pent-2-enoic acid amide substance P antagonist substantially as herein described with reference to any one of the Examples.